Bioxodes is a clinical-stage biopharmaceutical company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

European Commission

Bioxodes

We are so ready for the upcoming #bioequity Europe conference organised by EBD Group on May 15th!  Our CEO Marc Dechamps will give a presentation on the latest developments of the company and the progress of our first-in-class drug candidate, Ir-CPI, for patients with #IntraCerebral #Hemorrhage (#ICH)

You can already check out our company presentation on the #partneringone platform.  Looking forward to fruitful meetings in Dublin, contact us if you want to meet!

https://lnkd.in/eAdBMpBQ

PRESS RELEASE!
We are pleased to announce our busy spring schedule where the team will present latest developments at key international conferences - on first-in-class drug candidate for patients with #intracerebral #hemorrhage :

🔺 Bioxodes to give presentation at #Bio€quity (May 14-16) and present posters at #ESOC (May 24-26) and #ISTH (June 24-28)
🔺 Company prepares Series A extension funding round for upcoming phase IIa and preparation of phase IIb clinical trials

Marc Dechamps, our CEO stated “We are thrilled to participate in these key events to present the progress of our first-in-class drug candidate, Ir-CPI, for patients with IntraCerebral Hemorrhage (ICH). 

There is currently a major unmet medical need, with no treatment option that can prevent acute secondary brain damage within the first 72 hours in patients exhibiting this pathology. 
We are working on our Series A funding round to help finance our phase IIa clinical trial for Ir-CPI and to be fully ready for the start of phase IIb.”

Read the full press release here: https://lnkd.in/ebD5F-uA 

Charlotte Corbisier Valérie Pireaux Edmond Godfroid 
#BioEquity Europe #ESOC2023 #ISTH2023 #SeriesA #stroke #ICH #phase2b #finance

This week, our CEO Marc Dechamps shared his testimonial as an entrepreneur and board member of HealthTech For Care!  During the webinar, Marc explained his commitment to the organisation and the importance of gathering all players in the life sciences sector to bring their solutions to patients faster and position them at the center of innovation! 
Did you miss it?  Watch the replay via the link below and find out why participating at #HTID5 is a not to miss event for Bioxodes.
👉 REPLAY: https://lnkd.in/eAC7zpfv

#innovation #entrepreneur #ceo #lifesciences #webinar #patients #opportunity

https://lnkd.in/evQucGcg

Our CEO, Marc Dechamps, will present a corporate overview at Biotech Showcase™ on Tuesday, January 10, 2023, at 11:30 am PST. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference.

For more information, please visit https://bioxodes.com/

#biotechshowcase #clinicaltrials #stroke #healthcareinnovation

We are thrilled to welcome Marc Dechamps as our new Chief Executive Officer. We are now ready to finalize the fundraising for the Phase IIa and to test our lead drug candiate Ir-CPI in patients with intracerebral hemorrhage. 
Bioxodes' founder, Edmond Godfroid, will take up the post of Chief Operations Officer alongside his existing responsibilities as Chief Scientific Officer.

#biotech #clinicaltrials  #fundraising

Less than one week before HTID#4 event in Paris. Let's meet and discuss about our new developments in intracerebral haemorrhage.

#biotech #HTID #clinicaltrials

Join Bioxodes at the HeathTech Innovation Days in Paris on October 13th and 14th, 2022. We'll be happy to discuss about our lead drug candidate Ir-CPI and the new developments in intracerebral haemorrhage.

#biotech  #clinicaltrials #drugdevelopment #HTID

COM:BIOXODES

Bioxodes

Analysis Not Available